Skip to content

Home - Media - Press releases - 2001    
26 November 2001
ASTRAZENECA RECEIVES SIX MONTHS’ MARKET EXCLUSIVITY FOR ZESTRIL® (LISINOPRIL)

AstraZeneca announced today that the U.S. Food and Drug Administration (FDA) granted six months’ market exclusivity for the ACE inhibitor ZESTRIL® (lisinopril) after the company complied with the FDA’s written request for information on the use of the medication in children.

The additional six months’ exclusivity extends AstraZeneca’s US market protection for currently marketed drug products containing lisinopril, which include ZESTRIL® and ZESTORETIC® (lisinopril and hydrochlorthiazide) Tablets, through June 29, 2002.

Further enquires to:

Media Relations

Emily Denney
+44 (0)20 7304 5034

Steve Brown
+44 (0)20 7304 5033


Investor Relations

Jorgen Winroth
+1 609 896 4148

Mina Blair-Robinson
+44 (0)20 7304 5084
AstraZeneca websites
Search
 Terms of use  Privacy policy    © AstraZeneca PLC 2003 - 2008